Literature DB >> 20484619

Population pharmacokinetic modeling of pantoprazole in pediatric patients from birth to 16 years.

W Knebel1, B Tammara, C Udata, G Comer, M R Gastonguay, X Meng.   

Abstract

The population pharmacokinetics of pantoprazole was characterized in pediatric patients from birth to 16 years using NONMEM and evaluated via bootstrap and predictive check. Data were described using a 2-compartment model with a typical parameterized in terms of clearance (CL) (95% CI) of 1.93 L per hour (1.53, 2.61), given the reference covariates (female, full term, extensive/unknown CYP2C19 metabolizer status, non-African American, 10 kg weight, intravenous or tablet administration). Pantoprazole pharmacokinetic parameters appear to be similar in pediatric patients compared to adults when allometrically scaled. The effect of age on allometrically scaled CL was best described by a sigmoid Emax model with the age effect reaching an asymptote approximately equal to the adult CL by 1 year. CYP2C19 poor metabolizers exhibited reduced CL with the point estimate and 95% CI more than 70% lower than the typical value. Simulations from the final model indicated that the 1.2-mg/kg dose provides the best comparison to adults.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20484619     DOI: 10.1177/0091270010366146

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  9 in total

1.  CYP2C19 Phenotype and Risk of Proton Pump Inhibitor-Associated Infections.

Authors:  Christiana J Bernal; Ida Aka; Robert J Carroll; Joseph R Coco; John J Lima; Sari A Acra; Dan M Roden; Sara L Van Driest
Journal:  Pediatrics       Date:  2019-11-07       Impact factor: 7.124

2.  Developmental pharmacogenetics of CYP2C19 in neonates and young infants: omeprazole as a probe drug.

Authors:  Wei Zhao; Stéphanie Leroux; Valérie Biran; Evelyne Jacqz-Aigrain
Journal:  Br J Clin Pharmacol       Date:  2018-03-09       Impact factor: 4.335

3.  A Population-Based Pharmacokinetic Model Approach to Pantoprazole Dosing for Obese Children and Adolescents.

Authors:  Valentina Shakhnovich; P Brian Smith; Jeffrey T Guptill; Laura P James; David N Collier; Huali Wu; Chad E Livingston; Jian Zhao; Gregory L Kearns; Michael Cohen-Wolkowiez
Journal:  Paediatr Drugs       Date:  2018-10       Impact factor: 3.930

4.  Utility of the 13 C-pantoprazole breath test as a CYP2C19 phenotyping probe for children.

Authors:  Keith Feldman; Gregory L Kearns; Robin E Pearce; Susan M Abdel-Rahman; James Steven Leeder; Alec Friesen; Vincent S Staggs; Andrea Gaedigk; Jaylene Weigel; Valentina Shakhnovich
Journal:  Clin Transl Sci       Date:  2022-02-14       Impact factor: 4.438

5.  Comparable liraglutide pharmacokinetics in pediatric and adult populations with type 2 diabetes: a population pharmacokinetic analysis.

Authors:  Kristin C Carlsson Petri; Lisbeth V Jacobsen; David J Klein
Journal:  Clin Pharmacokinet       Date:  2015-06       Impact factor: 6.447

6.  Clinical Pharmacogenetics of Cytochrome P450-Associated Drugs in Children.

Authors:  Ida Aka; Christiana J Bernal; Robert Carroll; Angela Maxwell-Horn; Kazeem A Oshikoya; Sara L Van Driest
Journal:  J Pers Med       Date:  2017-11-02

7.  Genotype tailored treatment of mild symptomatic acid reflux in children with uncontrolled asthma (GenARA): Rationale and methods.

Authors:  Monica Tang; Kathryn V Blake; John J Lima; Edward B Mougey; James Franciosi; Stephan Schmidt; Md Jobayer Hossain; Marjan Cobbaert; Bernard M Fischer; Jason E Lang
Journal:  Contemp Clin Trials       Date:  2019-01-16       Impact factor: 2.226

Review 8.  Proton pump inhibitors in pediatrics : mechanism of action, pharmacokinetics, pharmacogenetics, and pharmacodynamics.

Authors:  Robert M Ward; Gregory L Kearns
Journal:  Paediatr Drugs       Date:  2013-04       Impact factor: 3.022

9.  Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing.

Authors:  John J Lima; Cameron D Thomas; Julia Barbarino; Zeruesenay Desta; Sara L Van Driest; Nihal El Rouby; Julie A Johnson; Larisa H Cavallari; Valentina Shakhnovich; David L Thacker; Stuart A Scott; Matthias Schwab; Chakradhara Rao S Uppugunduri; Christine M Formea; James P Franciosi; Katrin Sangkuhl; Andrea Gaedigk; Teri E Klein; Roseann S Gammal; Takahisa Furuta
Journal:  Clin Pharmacol Ther       Date:  2020-09-20       Impact factor: 6.903

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.